$Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma$

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the retreat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Anna Emanuele Pareto, Marco Picardi, Lucio Catalano, Fabrizio Pane
Format:	Article
Language:	English
Published:	Wiley 2016-01-01
Series:	Case Reports in Hematology
Online Access:	http://dx.doi.org/10.1155/2016/6745286
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
by: Mohammadreza Eslami, et al.
Published: (2024-01-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020-01-01)

Bendamustine Associated with Irreversible Ascending Paralysis
by: Ashraf Alhafez, et al.
Published: (2013-01-01)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
by: Vania dos Santos Nunes-Nogueira, et al.
Published: (2022-06-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
by: Jan Van Keer, et al.
Published: (2016-01-01)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
by: Rūta Čepulytė, et al.
Published: (2020-01-01)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
by: Mehmet Akce, et al.
Published: (2016-01-01)

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
by: Shigeki Ito, et al.
Published: (2013-01-01)

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
by: Xuejie Gao, et al.
Published: (2025-01-01)

An NMR Study of the Bortezomib Degradation under Clinical Use Conditions
by: Adele Bolognese, et al.
Published: (2009-01-01)

Relapse of Multiple Myeloma Presenting with Biliary Obstruction
by: Alan Coss, et al.
Published: (2010-01-01)

Detection of early relapse in multiple myeloma patients
by: Tereza Růžičková, et al.
Published: (2025-01-01)

Treatment of Severe Refractory Hematuria due to Radiation-Induced Hemorrhagic Cystitis with Dexamethasone
by: José Carlos Rodrigues Nascimento, et al.
Published: (2017-01-01)

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01)

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
by: Zewei Chen, et al.
Published: (2025-02-01)

Relapse of Multiple Myeloma Presenting as Extramedullary Plasmacytomas in Multiple Organs
by: Murat Köse, et al.
Published: (2015-01-01)

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2025-01-01)

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
by: Huamao Mark Lin, et al.
Published: (2019-01-01)

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
by: Inés Zugasti, et al.
Published: (2025-02-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Policy change or tactical retreat?
by: Wishes Tendayi Mututwa, et al.
Published: (2022-10-01)

Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma
by: Abdulbaril Olagunju, et al.
Published: (2022-01-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
by: Heather Katz, et al.
Published: (2019-01-01)

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia
by: E. Vandeix, et al.
Published: (2012-01-01)